Home > Protocol Summaries: Compounds > Orvepitant

Protocol Summaries: Orvepitant

Protocol Summaries for Orvepitant
GSK
Study ID		 Phase Title Status
110355 Phase 1 A open-label, randomized, single-dose, 3-way crossover study to investigate the pharmacokinetics, safety and tolerability of 2 different formulations of orvepitant and the effect of food in healthy volunteers. Completed
110371 Phase 1 A Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 after Once-Daily Repeated Oral Doses in Healthy Male and Female Subjects Completed
110833 Phase 2 A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects with Major Depressive Disorder Recruiting
111733 Phase 2 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects with Major Depressive Disorder Recruiting
113211 Phase 2 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Post Traumatic Stress Disorder (PTSD) Active, not recruiting
NKG10004 Phase 1 A Parallel Group, Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 and its Effect on the Pharmacokinetics of Midazolam after Once-Daily Repeated Oral Doses in Healthy Subjects Completed

Filter list by: